Skip to Primary Navigation

PMCPA case highlights UK pharma compliance risks in comms with health pros

A photo of a translucent sign with "121" and "AstraZeneca" printed across it at the company's corporate headquarters.
Photo: Smith Collection/Gado/Getty Images

Case examines allegations involving AstraZeneca under the ABPI Code, underscoring the compliance controls drugmakers need to implement.

The UK pharmaceutical industry’s self-regulatory body has published its findings in a complaint brought by a health professional against a major pharmaceutical company.

The case reveals the high degree of scrutiny applied by regulators and industry watchdog groups to how drugmakers manage communications and engagement with healthcare professionals. The

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience